Please visit www.OxytrolForWomen.com for more information.About OXYTROL ® FOR WOMEN OXYTROL ® FOR WOMEN is the only over-the-counter treatment available for overactive bladder in women. The OXYTROL FOR WOMEN patch provides transdermal delivery of oxybutynin, an active ingredient used to treat OAB for more than 30 years. Each OXYTROL FOR WOMEN patch delivers 3.9 mg of oxybutynin per day for a continuous four days and nights. Merck licensed the exclusive rights to market, distribute and sell OXYTROL as an OTC treatment for OAB from Actavis, Inc. (NYSE: ACT), formerly known as Watson Pharmaceuticals, Inc. OXYTROL ® (oxybutynin transdermal system) is a registered trademark of Watson Pharma, Inc. About Merck Consumer Care Today's Merck is a global healthcare leader working to help the world be well. Merck Consumer Care is a subsidiary of Merck & Co., Inc. Each day, millions count on one or more of our industry-leading brands that help prevent or treat various common conditions. These include household names such as CLARITIN ® for allergies, COPPERTONE ® for sun care, DR. SCHOLL'S ® for foot care, and many more. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube. Merck Forward-Looking Statement This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.